Endocrinology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)
The American Journal of Cardiology, 06/22/09

Robinson JG et al. – Ezetimibe/simvastatin (E/S) is more likely to result in lipid treatment endpoints than atorvastatin and was generally well tolerated at the compared doses.

Methods

Double-blind, randomized, 6-week study of lipid-lowering efficacy of E/S 10/20 mg vs atorvastatin 10 or 20 mg, and E/S 10/40 mg vs atorvastatin 40 mg
Subjects: 1,128 pts with hypercholesterolemia and the metabolic syndrome
Primary endpoint: percentage of change from baseline in low-density lipoprotein (LDL) cholesterol
Additional endpoints: changes in other lipids, lipoprotein ratios, high-sensitivity C-reactive protein, and attainment of pre-specified lipid levels

Results

Significantly greater improvements in levels of LDL cholesterol, non–high-density lipoprotein cholesterol, apolipoprotein B, and lipid/lipoprotein ratios with E/S vs atorvastatin at all dose comparisons
Attainment of prespecified LDL cholesterol and non–high-density lipoprotein cholesterol levels significantly greater with E/S vs atorvastatin at all dose comparisons
High-density lipoprotein cholesterol increases significantly greater with E/S 10/20 mg vs atorvastatin 10 mg and E/S 10/40 mg vs atorvastatin 40 mg
Changes in triglycerides, very low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein similar for both treatments
Low incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events, generally similar to those in previous studies of E/S and/or atorvastatin

<< Previous
A review of insulin and insulin regimens in type 2 diabetes

Next >>
Effects of a Higher-Carbohydrate/Lower-Fat Diet Versus a...